Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Trial Profile

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2015

At a glance

  • Drugs Evinacumab (Primary)
  • Indications Metabolic disorders
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 29 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 16 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
    • 16 Mar 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top